Tyligand Bioscience
PrivateLast Round
IPO
Jan 29, 2026
Est. Valuation
$222.2M
Total Funding Raised
$74.61M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Tyligand Bioscience operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series B round in April 2024.
Tyligand Bioscience is a biotechnology company that focuses on the discovery and development of innovative small molecule therapeutics and antibody-drug conjugates for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tyligand Bioscience Comparables
Compare Tyligand Bioscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kumquat Biosciences | 83% | |
| BridgeBio Oncology | 83% | |
| Jacobio Pharmaceuticals Group Co Ltd | 81% |
For institutional investors. Book with your work email.
Tyligand Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Jan 29, 2026 | ||||
| Series B | Apr 1, 2024 | ||||
| Series A Extension | Nov 1, 2022 | ||||
| Series A | Apr 1, 2021 | ||||
| Pre Seed | Sep 1, 2018 |
For institutional investors. Book with your work email.
Tyligand Bioscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ming Bioventures | Series A Extension |
| Medfine Capital | Pre Seed |
| Yijing Capital | Series A |
| 险峰K2VC | Pre Seed |
| Lilly Asia Ventures | Series B |
| Hongli Innovation Investment | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 29, 2026
Completed IPO at $275M pre-money valuation.
- Apr 1, 2024
$27M round led by Lilly Asia Ventures.
For institutional investors. Book with your work email.
Tyligand Bioscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Tyligand Bioscience's valuation, stock price, and market status.
Is Tyligand Bioscience a public or private company?
Tyligand Bioscience is a private company.
What is the current stock price of Tyligand Bioscience?
Tyligand Bioscience is a private company, so its shares have no public market price. Caplight tracks Tyligand Bioscience's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Tyligand Bioscience worth (valuation)?
Tyligand Bioscience's valuation is estimated at $222.2M based on funding round data.
Can I buy Tyligand Bioscience stock?
Tyligand Bioscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Tyligand Bioscience's last funding round?
Tyligand Bioscience's most recent funding round was IPO on January 29, 2026.
Who are the main investors in Tyligand Bioscience?
Key investors in Tyligand Bioscience include Ming Bioventures.
Will Tyligand Bioscience IPO soon?
No public IPO plans have been announced for Tyligand Bioscience.
How can I track Tyligand Bioscience secondary market activity?
Caplight tracks bids, offers, and trades in Tyligand Bioscience's shares on secondary markets.